Metastatic castration-resistant prostate cancer (mCRPC) poses a substantial challenge in oncology, characterized by its complexity, treatment resistance, and profound impact on patients’ lives. Although recent advancements in therapy have broadened treatment options and extended survival rates, unequal access to these innovations persists due to various clinical, systemic, and financial obstacles. By incorporating clinical benefits and patient-centered outcomes into the drug development process, trials can optimize access for patients after regulatory approval.
Read our white paper to learn more about:
- The multiple facets of the disease burden
- Effects on patients and caregivers, and critical clinical outcomes
- How to use this to inform policy decisions on formulary inclusion and reimbursement
